Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer

Satoshi Tamada; Taro Iguchi; Minoru Kato; Jumpei Asakawa; Kazuaki Kita; Sayaka Yasuda; Takeshi Yamasaki; Yudai Matsuoka; Kazuyuki Yamaguchi; Kentaro Matsumura; Ishun Go; Tetsuji Ohmachi; Tatsuya Nakatani

doi:10.18632/oncotarget.26426

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer

Satoshi Tamada _, Taro Iguchi, Minoru Kato, Jumpei Asakawa, Kazuaki Kita, Sayaka Yasuda, Takeshi Yamasaki, Yudai Matsuoka, Kazuyuki Yamaguchi, Kentaro Matsumura, Ishun Go, Tetsuji Ohmachi and Tatsuya Nakatani

PDF | HTML | How to cite

Oncotarget. 2018; 9:36966-36974. https://doi.org/10.18632/oncotarget.26426

Metrics: PDF 1654 views | HTML 2547 views | ?

Abstract

Satoshi Tamada1, Taro Iguchi1, Minoru Kato1, Jumpei Asakawa1, Kazuaki Kita1, Sayaka Yasuda1, Takeshi Yamasaki1, Yudai Matsuoka2, Kazuyuki Yamaguchi2, Kentaro Matsumura2, Ishun Go2, Tetsuji Ohmachi2 and Tatsuya Nakatani1

1Department of Urology, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka 545–8585, Japan

2Department of Urology, Bell Land General Hospital, Naka-ku, Sakai City, Osaka 599–8247, Japan

Correspondence to:

Satoshi Tamada, email: [email protected]

Keywords: castration-resistant prostate cancer; combined androgen blockade; hormone-sensitive prostate cancer; progression; survival

Received: September 19, 2018 Accepted: November 26, 2018 Published: December 11, 2018

ABSTRACT

Purpose: The aim of our retrospective study was to determine the time to progression to castration-resistant prostate cancer (CRPC) in prostate cancer patients who undergo combined androgen blockade (CAB), as well as their prognoses.

Materials and Methods: We examined the overall survival (OS) and disease-specific survival rates, as well as the time to CRPC development, in 387 patients who were treated with CAB for prostate cancer. The disease-specific survival rate and time to CRPC were stratified by prostate-specific antigen (PSA) levels, Gleason score (GS), and presence of metastasis at diagnosis. We designated high-risk patients as those satisfying at least two of the following three criteria: extent of disease of bone metastasis grade ≥2, presence of metastasis at diagnosis, and a GS ≥8.

Results: The 10- and 15-year OS rates were 74.0% and 50.4%, respectively, while the corresponding disease-specific survival rates were both 86.8%. Metastasis at diagnosis was an independent prognostic factor for disease-specific survival. The median time to CRPC development was 140.7 months. A PSA level ≥20 ng/mL, a GS ≥8, and the presence of metastasis at diagnosis were independent predictors of a shorter time to CRPC development. The 10-year disease-specific survival rate in the high-risk group was significantly lower than that in the low-risk group (approximately 74% vs. 98%), and the time to CRPC development was significantly shorter (median: 20.5 months vs. not reached).

Conclusions: The time to CRPC development was shorter in high-risk prostate cancer patients with metastases. Such patients require alternative novel treatment modalities.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26426

Publication Alerts

Research Papers:

Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer

Abstract